| Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. | |
| | |
MedLine Citation:
|
PMID: 18376308 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: There is much accumulated evidence that EGFR, HER2, and their downstream signaling pathway members such as KRAS, BRAF, and PIK3CA are strongly implicated in cancer development and progression. Recently, mutations in the kinase domains of EGFR and HER2, associated with increased sensitivity to tyrosine kinase inhibitors, have been described. METHODS: To evaluate the mutational status of these genes in intraductal papillary mucinous neoplasm (IPMN)/intraductal papillary mucinous carcinoma (IPMC), EGFR and HER2 were analyzed in 36 IPMN/IPMC, and the results were correlated to the mutational status of the KRAS, BRAF, and PIK3CA genes in the samples. RESULTS: Together, we identified 1 silent mutation of HER2, 17 (43%) KRAS mutations, 1 (2.7%) BRAF mutation, and 4 (11%) mutations of PIK3CA in the IPMN/IPMC samples. CONCLUSIONS: The EGFR and ERBB2 (HER2) mutations are very infrequent in IPMN/IPMC, suggesting the limited possibility of targeting mutated ERBB2 and EGFR for therapy for these lesions. The KRAS, BRAF, and PIK3CA, however, could represent interesting targets for future therapies in these lesions. |
| | |
Authors:
|
Frank Schönleben; John D Allendorf; Wanglong Qiu; Xiaojun Li; Daniel J Ho; Nancy T Ciau; Robert L Fine; John A Chabot; Helen E Remotti; Gloria H Su |
Related Documents
:
|
23653008 - The novel human mrc1 gene polymorphisms are associated with susceptibility to pulmonary... 20361188 - Acquired kras mutations during progression of colorectal cancer metastases: possible im... 18466578 - Application of structural equation models to construct genetic networks using different... 19775298 - Germ-line mutation of the nras gene may be responsible for the development of juvenile ... 20976178 - Coaims: a cost-effective panel of ancestry informative markers for determining continen... 18389388 - Mutation spectrum in hnpcc in the israeli population. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Pancreas Volume: 36 ISSN: 1536-4828 ISO Abbreviation: Pancreas Publication Date: 2008 Mar |
Date Detail:
|
Created Date: 2008-03-31 Completed Date: 2008-06-19 Revised Date: 2012-06-21 |
Medline Journal Info:
|
Nlm Unique ID: 8608542 Medline TA: Pancreas Country: United States |
Other Details:
|
Languages: eng Pagination: 168-72 Citation Subset: IM |
Affiliation:
|
Department of Otolaryngology/Head and Neck Surgery, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma, Mucinous
/
enzymology,
genetics*,
mortality,
pathology Aged Aged, 80 and over Carcinoma, Intraductal, Noninfiltrating / enzymology, genetics*, mortality, pathology Cohort Studies Female Gene Expression Regulation, Enzymologic Gene Expression Regulation, Neoplastic* Humans Kaplan-Meier Estimate Male Middle Aged Mutation* Neoplasm Staging Oncogenes* Pancreatic Neoplasms / enzymology, genetics*, mortality, pathology Phosphatidylinositol 3-Kinases / genetics Proto-Oncogene Proteins / genetics Proto-Oncogene Proteins B-raf / genetics Receptor, Epidermal Growth Factor / genetics Receptor, erbB-2 / genetics ras Proteins / genetics |
| Grant Support | |
ID/Acronym/Agency:
|
CA95434/CA/NCI NIH HHS; K01 CA095434-05/CA/NCI NIH HHS; R01 CA109525/CA/NCI NIH HHS; R01 CA109525-03/CA/NCI NIH HHS; R01 CA109525-04/CA/NCI NIH HHS; R01 CA109525-05/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/KRAS protein, human; 0/Proto-Oncogene Proteins; EC 2.7.1.-/Phosphatidylinositol 3-Kinases; EC 2.7.1.137/PIK3CA protein, human; EC 2.7.10.1/EGFR protein, human; EC 2.7.10.1/ERBB2 protein, human; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptor, erbB-2; EC 2.7.11.1/BRAF protein, human; EC 2.7.11.1/Proto-Oncogene Proteins B-raf; EC 3.6.5.2/ras Proteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pan...
Next Document: Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.